Use of Phenytoin, Phenobarbital Carbamazepine, Levetiracetam Lamotrigine and Valproate in Pregnancy and Breastfeeding: Risk of Major Malformations, Dose-dependency, Monotherapy vs Polytherapy, Pharmacokinetics and Clinical Implications

(E-pub Ahead of Print)

Author(s): Yusuf Cem Kaplan*, Omer Demir

Journal Name: Current Neuropharmacology

Become EABM
Become Reviewer
Call for Editor


It is challenging to balance the fetal risks associated with the use of antiepileptic drugs (AEDs) against maternal and fetal risks of seizure worsening and therefore it is very important to define and distinguish the possible risks entailed by different AEDs. This paper aims to undertake a comprehensive review regarding the possible risks of four classical (phenytoin, carbamazepine, phenobarbital and valproate) and two newer (lamotrigine and levetiracetam) AEDs during pregnancy. The review focuses on major and organ-specific malformations, dose-dependent risks, mono vs polytherapy, and clinical pharmacokinetics. A discussion regarding the safety of AED use during breastfeeding is also provided.

Keywords: pregnancy, breastfeeding, antiepileptics, major malformations, phenytoin, carbamazepine, phenobarbital, valproate, lamotrigine, levetiracetam

Rights & PermissionsPrintExport Cite as

Article Details

Published on: 11 February, 2021
(E-pub Ahead of Print)
DOI: 10.2174/1570159X19666210211150856
Price: $95

Article Metrics

PDF: 255